Levine James E. has filed 6 insider transactions across 1 company since March 2023.
Most recent transaction: a grant/award of 332621 shares of Cardiff Oncology, Inc. ($CRDF) on March 11, 2025.
Activity breakdown: 3 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2025 | Cardiff Oncology, Inc. | $CRDF | Levine James E. | Chief Financial Officer | A | Stock Options | 332621 | $0.00 | 1,295,117.0000 | 66,524,294 | 34.56% | 0.50% |
| Dec. 16, 2024 | Cardiff Oncology, Inc. | $CRDF | Levine James E. | Chief Financial Officer | P | Common Stock | 2564 | $3.83 | 62,564.0000 | 0 | 4.27% | 0.00% |
| Dec. 17, 2024 | Cardiff Oncology, Inc. | $CRDF | Levine James E. | Chief Financial Officer | P | Common Stock | 2752 | $5.42 | 65,316.0000 | 0 | 4.40% | 0.00% |
| Dec. 18, 2024 | Cardiff Oncology, Inc. | $CRDF | Levine James E. | Chief Financial Officer | P | Common Stock | 2400 | $5.00 | 67,716.0000 | 0 | 3.67% | 0.00% |
| March 7, 2024 | Cardiff Oncology, Inc. | $CRDF | Levine James E. | Chief Financial Officer | A | Stock Options | 205008 | $0.00 | 962,496.0000 | 0 | 27.06% | 0.00% |
| March 15, 2023 | Cardiff Oncology, Inc. | $CRDF | Levine James E. | Chief Financial Officer | A | Stock Options | 197472 | $0.00 | 757,488.0000 | 0 | 35.26% | 0.00% |